Cardiff Oncology, Inc. Common Stock (CRDF) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDF trades at $1.84 with a market cap of $115.55M and a P/E ratio of -1.95. CRDF moved +4.55% today. Year to date, CRDF is -35.21%; over the trailing twelve months it is -40.07%. Its 52-week range spans $1.48 to $5.64. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces CRDF's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CRDF financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CRDF recently traded at $1.84. Market cap is $115.55M. P/E ratio is -1.95. Revenue is $488.00K.
| Metric | Value |
|---|---|
| Price | $1.84 |
| Market Cap | $115.55M |
| P/E Ratio | -1.95 |
| EPS | $-0.93 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.64 |
| 52-Week Low | $1.48 |
| Volume | 1.73M |
| Avg Volume | 0 |
| Revenue (TTM) | $488.00K |
| Net Income | $-41.44M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2023 | $488.00K | $-41.44M | $-0.93 |
| 2022 | $386.00K | $-38.70M | $-0.89 |
| 2021 | $359.00K | $-28.29M | $-0.73 |
| 2020 | $365.99K | $-19.31M | $0.00 |
6 analysts cover CRDF: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.33.